Update on integrated biomarkers for assessment of long-term risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis

Annals of Medicine

Volumn 41, Issue 5, 2009, Pages 332-343

  Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Biomarker; Cardiovascular risk assessment; Integrated approach

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPOCYTOKINE; ALPHA 1 ANTITRYPSIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERULOPLASMIN; CYSTATIN C; D DIMER; FIBRINOGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 6; LEUKOCYTE ELASTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; OROSOMUCOID; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SECRETORY PHOSPHOLIPASE A2; SERUM AMYLOID A; SERUM AMYLOID P; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TROPONIN I;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INFLAMMATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INVASIVE PROCEDURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; METHODOLOGY; PROGNOSIS; RISK FACTOR; TIME;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 67449087049     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890902769675     Document Type: Review

References (68)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silber-shatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847
2. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) study. Circulation. 2002;105:310-315
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-1610
4. Greenland P. Improving risk of coronary heart disease: can a picture make the difference? JAMA. 2003;289:2270-2272
5. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290: 898-904.
6. Law MR, Wald NJ, Morris JK. The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. J Med Screen. 2004;11:3-7.
7. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391
8. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15-26.
9. Bisoendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis. 2007;195:e10-8.
10. The Emerging Risk Factors Collaboration; Danesh J, Ergou S, Walker M, Thompson SG, Tipping R, Ford C, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22:839-869
11. Kimberly MM, Vesper HW, Caudill SP, Cooper GR, Rifai N, Dati F, et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem. 2003; 49:611-616
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
13. Fibrinogen Studies Collaboration; Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA. 2005;294:1799-1809
14. Khuseyinova N, Koenig W Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholi-pase A(2) fit in? Mol Diagn Ther. 2007;11:203-217
15. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006;114:381-387
16. Lowe GD, Sweetnam PM, Yarnell JW, Rumley A, Rumley C, Bainton D, et al. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol. 2004;24:1957-1962
17. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002;105:2632-2637 (Pubitemid 34596040)
18. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007; 115:2119-2127
19. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419
20. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397
21. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110: 1903-1908
22. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479-2484
23. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schafer G, Seelhorst U, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53:1440-1447
24. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bru-neck study. Arterioscler Thromb Vasc Biol. 2007;27: 1788-1795
25. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369-1377
26. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639
27. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116
28. de Lemos JA, Lloyd-Jones DM. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med. 2008;358: 2172.
29. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. HOPE Study Investigators. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201-208
30. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358: 1240-1249
31. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210-215
32. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158-165
33. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-1870
34. Lakoski SG, Greenland P, Wong ND, Schreiner PJ, Herring-ton DM, Kronmal RA, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as ?low risk? based on Framingham risk score: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2007;167:2437-2442
35. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358: 1336-1345
36. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al.; American Heart Association Committee on Cardiovascular Imaging and Intervention; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Committee on Cardiac Imaging; Council on Clinical Cardiology. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation. 2006;114:1761-1791
37. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-467
38. Baldassarre D, Amato M, Pustina L, Castelnuovo S, Sanvito S, Gerosa L, et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis. 2007;191:403-408
39. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262-269
40. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431-440
41. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol. 2003;23:554-566
42. Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation. 2006;113:601-603
43. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657-663 (Pubitemid 43754329)
44. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmus-sen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664-670
45. Heald CL, Fowkes FG, Murray GD, Price JF; Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis. 2006;189:61-69
46. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114:688-699
47. Diehm C, Lange S, Darius H, Pittrow D, von Stritzky B, Tepohl G, et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J. 2006;27:1743-1749
48. Lee AJ, Price JF, Russell MJ, Smith FB, van Wijk MC, Fowkes FG. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation. 2004;110:3075-3080
49. Wyman RA, Keevil JG, Busse KL, Aeschlimann SE, Korcarz CE, Stein JH. Is the ankle-brachial index a useful screening test for subclinical atherosclerosis in asymptomatic, middle-aged adults? WMJ. 2006;105:50.
50. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al.; for Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis. JAMA. 2008;300:197-208.
51. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: PartI. Circulation. 2003;108:1664-1672 (Pubitemid 37243650)
52. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-1778 (Pubitemid 37296082)
53. Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events Circulation. 2006;114:2390-2411
54. Simon A, Chironi G, Levenson J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J. 2007;28:2967-2971
55. Jacobs DR Jr, Crow RS. Subclinical cardiovascular disease markers applicable to studies of oral health: multiethnic study of atherosclerosis. Ann N Y Acad Sci. 2007;1098:269-287
56. Bots ML, Baldassarre D, Simon A, de Groot E, O?Leary DH, Riley W, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007;28:398-406 (Pubitemid 47343565)
57. Price JF, Tzoulaki I, Lee AJ, Fowkes FG. Ankle brachial index and intima media thickness predict cardiovascular events similarly and increased prediction when combined. J Clin Epidemiol. 2007;60:1067-1075
58. Park R, Detrano R, Xiang M, Fu P, Ibrahim Y, LaBree L, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002;106:2073-2077
59. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation. 2007;116:32-38
60. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890
61. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949-952
62. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007; 115:928-935
63. Pencina MJ, D?Agostino RB Sr, D?Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172
64. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619
65. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 2006;48:1733-1741
66. Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol. 2006;47:1328-1338
67. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE. 2006;1:e97.
68. Stern S. Are we getting nearer to screening for atherosclerosis? Circulation. 2008;117:122-126